Skip to content

Impact of Octreotide on Renal Function of Patients after Liver Transplantation

Impact of Octreotide on Renal Function of Patients after Liver Transplantation; A Randomized, Double-Blind, Placebo-Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190619043942N1
Enrollment
60
Registered
2021-12-09
Start date
2021-07-23
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplantation. Liver transplant status

Interventions

Intervention 1: intervention group 1: octerotide 50 mg / h intravenous infusion for three days from one of the Domestic manufacturer factory that will be provided by Namazi Hospital Intervention. Inte

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age between 18 and 60 years 2.Cirrhosis of the liver defined by clinical, biochemical or histological That, properly informed, give their consent to participate in the study and undergo tests and examinations that entails Women of childbearing potential: pregnancy test negative serum or urine, and acceptance of use of adequate contraception since at least 14 days prior to the first dose of study drug until 14 days after the last dose

Exclusion criteria

Exclusion criteria: 1.Pregnant women, nursing mothers, or those who intend to become pregnant during the study period 2.Systolic blood pressure = 150 mmHg and / or diastolic blood pressure = 90 mmHg 3.Previous treatment with transjugular intrahepatic portosystemic shunt (TIPS) or surgical portosystemic shunts 4.Simultaneous Liver, Kidney Transplant 5.Cardiac or respiratory failure 6.Positive for human immunodeficiency virus 7.Urinary retention 8.Ischemic heart disease or peripheral vascular disease 9.Narrow Angle Glaucoma 10.Cerebrovascular occlusions 11.Aortic Aneurysm 12.Thyrotoxicosis 13.Pheochromocytoma 14.Diabetes Melitus 15.History of Hemodialysis prior to Liver Transplant 16.PreTransplant Cr more than 2.5mg/dl

Design outcomes

Primary

MeasureTime frame
1. Glomerular filtration. Timepoint: 3 Days after Intervention, 1week after Intervention, 4 weeks after Intervention. Method of measurement: Change in glomerular filtration rate measured by isotopic tests.

Secondary

MeasureTime frame
Changes in renal function. Timepoint: 3days, 1 week, 4 weeks after cessation of treatment. Method of measurement: Lab test.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactkamran bagheri lankarani

Shiraz University of Medical Sciences

lankaran@sums.ac.ir+98 71 3230 9615

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026